CARMOT THERAPEUTICS
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases. They employ their patented technology, Chemotype Evolution, to address the fundamental causes of disease and speed the discovery of disease-modifying therapies. Carmot Therapeutics is headquartered in San Francisco, California and was founded in 2008.
CARMOT THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.carmot-therapeutics.us
Total Employee:
1+
Status:
Active
Contact:
5105279251
Total Funding:
234.85 M USD
Technology used in webpage:
SPF Google Apps For Business Unified Layer BlueHost BlueHost DNS BlueHost Mail
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Board_member
2020-09-01
Current Employees Featured
Stig K. Hansen Founder & CEO @ Carmot Therapeutics
Founder & CEO
2008-08-01
Aetna Wun Trombley Board Director @ Carmot Therapeutics
Board Director
2016-01-01
Founder
Investors List
Willett Advisors LLC
Willett Advisors LLC investment in Series D - Carmot Therapeutics
Deep Track Capital
Deep Track Capital investment in Series D - Carmot Therapeutics
The Column Group
The Column Group investment in Series D - Carmot Therapeutics
RA Capital Management
RA Capital Management investment in Series D - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series D - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series C - Carmot Therapeutics
The Column Group
The Column Group investment in Series C - Carmot Therapeutics
Amgen Ventures
Amgen Ventures investment in Series C - Carmot Therapeutics
The Column Group
The Column Group investment in Series B - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series B - Carmot Therapeutics
Official Site Inspections
http://www.carmot-therapeutics.us Semrush global rank: 5.15 M Semrush visits lastest month: 1.57 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Carmot Therapeutics"
Carmot Therapeutics Announces Completion of Acquisition by …
Jan 29, 2024 Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including …See details»
About Us | Carmot Therapeutics | Drug Discovery and Development
This platform enabled us to design a pipeline of incretin therapeutics intended to exhibit the appropriate balance of bias and desirable therapeutic attributes. Carmot’s founders had a …See details»
Carmot Therapeutics - Crunchbase Company Profile
Carmot Therapeutics may be growing as evidenced by the acquisition by Roche for up to $3.1 billion, which is a significant financial transaction indicating a …See details»
Carmot Therapeutics, Inc. - LinkedIn
Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on …See details»
Carmot Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Carmot Therapeutics Inc. of Berkeley, CA. Get the latest business insights from Dun & Bradstreet. ...See details»
Carmot Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors ... Carmot Therapeutics . 1: obfuscated. obfuscated. The Column …See details»
Genentech: Carmot Therapeutics
Carmot is currently conducting a double-blind, placebo-controlled Phase 1 clinical trial of CT-996 in participants with overweight or obesity, and in participants with T2D; it is designed to assess …See details»
Carmot Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Carmot Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Carmot Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Carmot Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 10 clinical trials, 107 news, and 12 literature, Disease Domain ...See details»
Carmot Therapeutics Inc. (CRMO) Company Profile & Overview
Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. …See details»
Our Approach | Carmot Therapeutics | Drug Discovery and …
Carmot was acquired by Roche in early 2024. Modulating core energy homeostatic pathways is critical to addressing this disease burden. Carmot’s clinical pipeline targets two main incretins, …See details»
Carmot Therapeutics Company Profile - Office Locations ... - Craft
Carmot Therapeutics is a clinical-stage biotechnology company focused on the discovery of disease-modifying therapies in metabolic disease and cancer. It applies a proprietary drug …See details»
Carmot Therapeutics, Inc. Company Overview, Contact Details ...
May 25, 2023 Key Personnel Moves Carmot Therapeutics has made strategic hires in executive positions like CEO and CMO, indicating a focus on leadership excellence and potentially …See details»
Carmot Therapeutics 2025 Company Profile: Valuation, Investors ...
Carmot Therapeutics General Information Description. Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living …See details»
Carmot Therapeutics expands leadership team and closes $47 …
Sep 30, 2020 Carmot Therapeutics, Inc. 740 Heinz Avenue Berkeley, CA 94710 www.carmot.us Carmot Therapeutics expands leadership team and closes $47 ... CA 94710 www.carmot.us …See details»
Carmot files for IPO, heating up icy market waters - Fierce Biotech
Nov 20, 2023 Obesity and diabetes-focused Carmot Therapeutics has unveiled plans to go public, braving icy IPO waters that have remained largely frozen over for biotech for more than …See details»
Partner Amgen becomes investor as Carmot pushes ... - Carmot …
Watson, who joined Carmot this year, led the series C fund-raising process. Previously, he was CEO of a life sciences investment bank and CBO and president of islet cell therapy at Flagship …See details»
Carmot Therapeutics Announces Significant Leadership Team …
Carmot Therapeutics, Inc. 740 Heinz Avenue Berkeley, CA 94710 www.carmot.us $425 million. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary …See details»
Carmot to receive royalty payments upon sales of FDA approved …
Carmot Therapeutics, Inc. 740 Heinz Avenue Berkeley, CA 94710 www.carmot.us Carmot to receive royalty payments upon sales of Amgen’s FDA approved first-in-class KRAS G12C …See details»
Carmot Therapeutics, Inc. (Carmot Therapeutics, Inc.) - 药物管线_ …
了解Carmot Therapeutics, Inc. (Carmot Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的10项临床试验, 90篇新闻和10篇文献，疾病领域:内分泌与代谢疾病，肿瘤，神经系 …See details»